Retrospective evaluation of deep transcranial magnetic stimulation as add-on treatment for Parkinson's disease

Francisco Torres, Esteban Villalon, Patricio Poblete, Rodrigo Moraga-Amaro, Sergio Linsambarth, Raúl Riquelme, Abraham Zangen, Jimmy Stehberg

Resultado de la investigación: Article

8 Citas (Scopus)

Resumen

Objective: To evaluate the safety and assess the different symptom improvements found after a combined low-frequency primary motor cortex and high-frequency prefrontal cortex (PFC) stimulation using the deep TMS (dTMS) H-coil, as an add-on treatment for Parkinson's disease (PD). Methods: Forty-five PD patients underwent 14 dTMS sessions; each consisting of 1 Hz stimulation of the primary motor cortex for 15 min, followed by 10 Hz stimulation of the PFC for 15 min. Clinical assessments were performed, BEFORE, at the MIDDLE, and END of therapy as well as at FOLLOW-UP after 30 days, using Movement Disorder Society-Unified Parkinson's Disease Rating Scale, TINETTI, UP&GO, SCOPA, HDRS 21, Beck Depression Inventory, and self-applied daily motor assessment scales. Results: Treatment was well-tolerated, without serious adverse effects. dTMS-induced significant PD symptom improvements at END and at FOLLOW-UP, in all subscales of the UPDRS, gait speed, depressive symptoms, balance, autonomic symptoms, and a 73% increase in daily ON time. Conclusion: In the cohort of PD patients treated, dTMS was well-tolerated with only minor adverse effects. The dTMS-induced significant improvements in motor, postural, and motivational symptoms of PD patients and may potentiate concurrent levodopa treatment. Significance: The present study demonstrates that dTMS may have a much wider spectrum of beneficial effects than previously reported for TMS, including enhancement of levodopa effects, suggesting that future clinical trials with dTMS should include a broader range of symptom measurements.

Idioma originalEnglish
Número de artículo210
PublicaciónFrontiers in Neurology
Volumen6
N.ºOCT
DOI
EstadoPublished - 2015

Huella dactilar

Transcranial Magnetic Stimulation
Parkinson Disease
Motor Cortex
Levodopa
Prefrontal Cortex
Therapeutics
Depression
Clinical Trials
Safety
Equipment and Supplies

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Citar esto

Torres, Francisco ; Villalon, Esteban ; Poblete, Patricio ; Moraga-Amaro, Rodrigo ; Linsambarth, Sergio ; Riquelme, Raúl ; Zangen, Abraham ; Stehberg, Jimmy. / Retrospective evaluation of deep transcranial magnetic stimulation as add-on treatment for Parkinson's disease. En: Frontiers in Neurology. 2015 ; Vol. 6, N.º OCT.
@article{6c96c61fd3c446d6b8d79d422aaf6ca1,
title = "Retrospective evaluation of deep transcranial magnetic stimulation as add-on treatment for Parkinson's disease",
abstract = "Objective: To evaluate the safety and assess the different symptom improvements found after a combined low-frequency primary motor cortex and high-frequency prefrontal cortex (PFC) stimulation using the deep TMS (dTMS) H-coil, as an add-on treatment for Parkinson's disease (PD). Methods: Forty-five PD patients underwent 14 dTMS sessions; each consisting of 1 Hz stimulation of the primary motor cortex for 15 min, followed by 10 Hz stimulation of the PFC for 15 min. Clinical assessments were performed, BEFORE, at the MIDDLE, and END of therapy as well as at FOLLOW-UP after 30 days, using Movement Disorder Society-Unified Parkinson's Disease Rating Scale, TINETTI, UP&GO, SCOPA, HDRS 21, Beck Depression Inventory, and self-applied daily motor assessment scales. Results: Treatment was well-tolerated, without serious adverse effects. dTMS-induced significant PD symptom improvements at END and at FOLLOW-UP, in all subscales of the UPDRS, gait speed, depressive symptoms, balance, autonomic symptoms, and a 73{\%} increase in daily ON time. Conclusion: In the cohort of PD patients treated, dTMS was well-tolerated with only minor adverse effects. The dTMS-induced significant improvements in motor, postural, and motivational symptoms of PD patients and may potentiate concurrent levodopa treatment. Significance: The present study demonstrates that dTMS may have a much wider spectrum of beneficial effects than previously reported for TMS, including enhancement of levodopa effects, suggesting that future clinical trials with dTMS should include a broader range of symptom measurements.",
keywords = "Deep TMS, H-coil, High and low frequency, Motor cortex, Parkinson's disease, Prefrontal cortex, Repetitive transcranial magnetic stimulation",
author = "Francisco Torres and Esteban Villalon and Patricio Poblete and Rodrigo Moraga-Amaro and Sergio Linsambarth and Ra{\'u}l Riquelme and Abraham Zangen and Jimmy Stehberg",
year = "2015",
doi = "10.3389/fneur.2015.00210",
language = "English",
volume = "6",
journal = "Frontiers in Neurology",
issn = "1664-2295",
publisher = "Frontiers Media S.A.",
number = "OCT",

}

Torres, F, Villalon, E, Poblete, P, Moraga-Amaro, R, Linsambarth, S, Riquelme, R, Zangen, A & Stehberg, J 2015, 'Retrospective evaluation of deep transcranial magnetic stimulation as add-on treatment for Parkinson's disease', Frontiers in Neurology, vol. 6, n.º OCT, 210. https://doi.org/10.3389/fneur.2015.00210

Retrospective evaluation of deep transcranial magnetic stimulation as add-on treatment for Parkinson's disease. / Torres, Francisco; Villalon, Esteban; Poblete, Patricio; Moraga-Amaro, Rodrigo; Linsambarth, Sergio; Riquelme, Raúl; Zangen, Abraham; Stehberg, Jimmy.

En: Frontiers in Neurology, Vol. 6, N.º OCT, 210, 2015.

Resultado de la investigación: Article

TY - JOUR

T1 - Retrospective evaluation of deep transcranial magnetic stimulation as add-on treatment for Parkinson's disease

AU - Torres, Francisco

AU - Villalon, Esteban

AU - Poblete, Patricio

AU - Moraga-Amaro, Rodrigo

AU - Linsambarth, Sergio

AU - Riquelme, Raúl

AU - Zangen, Abraham

AU - Stehberg, Jimmy

PY - 2015

Y1 - 2015

N2 - Objective: To evaluate the safety and assess the different symptom improvements found after a combined low-frequency primary motor cortex and high-frequency prefrontal cortex (PFC) stimulation using the deep TMS (dTMS) H-coil, as an add-on treatment for Parkinson's disease (PD). Methods: Forty-five PD patients underwent 14 dTMS sessions; each consisting of 1 Hz stimulation of the primary motor cortex for 15 min, followed by 10 Hz stimulation of the PFC for 15 min. Clinical assessments were performed, BEFORE, at the MIDDLE, and END of therapy as well as at FOLLOW-UP after 30 days, using Movement Disorder Society-Unified Parkinson's Disease Rating Scale, TINETTI, UP&GO, SCOPA, HDRS 21, Beck Depression Inventory, and self-applied daily motor assessment scales. Results: Treatment was well-tolerated, without serious adverse effects. dTMS-induced significant PD symptom improvements at END and at FOLLOW-UP, in all subscales of the UPDRS, gait speed, depressive symptoms, balance, autonomic symptoms, and a 73% increase in daily ON time. Conclusion: In the cohort of PD patients treated, dTMS was well-tolerated with only minor adverse effects. The dTMS-induced significant improvements in motor, postural, and motivational symptoms of PD patients and may potentiate concurrent levodopa treatment. Significance: The present study demonstrates that dTMS may have a much wider spectrum of beneficial effects than previously reported for TMS, including enhancement of levodopa effects, suggesting that future clinical trials with dTMS should include a broader range of symptom measurements.

AB - Objective: To evaluate the safety and assess the different symptom improvements found after a combined low-frequency primary motor cortex and high-frequency prefrontal cortex (PFC) stimulation using the deep TMS (dTMS) H-coil, as an add-on treatment for Parkinson's disease (PD). Methods: Forty-five PD patients underwent 14 dTMS sessions; each consisting of 1 Hz stimulation of the primary motor cortex for 15 min, followed by 10 Hz stimulation of the PFC for 15 min. Clinical assessments were performed, BEFORE, at the MIDDLE, and END of therapy as well as at FOLLOW-UP after 30 days, using Movement Disorder Society-Unified Parkinson's Disease Rating Scale, TINETTI, UP&GO, SCOPA, HDRS 21, Beck Depression Inventory, and self-applied daily motor assessment scales. Results: Treatment was well-tolerated, without serious adverse effects. dTMS-induced significant PD symptom improvements at END and at FOLLOW-UP, in all subscales of the UPDRS, gait speed, depressive symptoms, balance, autonomic symptoms, and a 73% increase in daily ON time. Conclusion: In the cohort of PD patients treated, dTMS was well-tolerated with only minor adverse effects. The dTMS-induced significant improvements in motor, postural, and motivational symptoms of PD patients and may potentiate concurrent levodopa treatment. Significance: The present study demonstrates that dTMS may have a much wider spectrum of beneficial effects than previously reported for TMS, including enhancement of levodopa effects, suggesting that future clinical trials with dTMS should include a broader range of symptom measurements.

KW - Deep TMS

KW - H-coil

KW - High and low frequency

KW - Motor cortex

KW - Parkinson's disease

KW - Prefrontal cortex

KW - Repetitive transcranial magnetic stimulation

UR - http://www.scopus.com/inward/record.url?scp=84946569239&partnerID=8YFLogxK

U2 - 10.3389/fneur.2015.00210

DO - 10.3389/fneur.2015.00210

M3 - Article

AN - SCOPUS:84946569239

VL - 6

JO - Frontiers in Neurology

JF - Frontiers in Neurology

SN - 1664-2295

IS - OCT

M1 - 210

ER -